JP2019013227A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019013227A5 JP2019013227A5 JP2018163436A JP2018163436A JP2019013227A5 JP 2019013227 A5 JP2019013227 A5 JP 2019013227A5 JP 2018163436 A JP2018163436 A JP 2018163436A JP 2018163436 A JP2018163436 A JP 2018163436A JP 2019013227 A5 JP2019013227 A5 JP 2019013227A5
- Authority
- JP
- Japan
- Prior art keywords
- halogen
- independently
- hydrogen
- oxo
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC1C(NC(N*=CC=C(C=*C)Oc2ccnc(*)*2C)=O)=CC=C(*)C(*)=C1 Chemical compound CC1C(NC(N*=CC=C(C=*C)Oc2ccnc(*)*2C)=O)=CC=C(*)C(*)=C1 0.000 description 2
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021086337A JP2021121219A (ja) | 2009-09-16 | 2021-05-21 | プロテインキナーゼコンジュゲート及びインヒビター |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24298809P | 2009-09-16 | 2009-09-16 | |
| US61/242,988 | 2009-09-16 | ||
| JP2015174949A JP6397389B2 (ja) | 2009-09-16 | 2015-09-04 | プロテインキナーゼコンジュゲート及びインヒビター |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015174949A Division JP6397389B2 (ja) | 2009-09-16 | 2015-09-04 | プロテインキナーゼコンジュゲート及びインヒビター |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021086337A Division JP2021121219A (ja) | 2009-09-16 | 2021-05-21 | プロテインキナーゼコンジュゲート及びインヒビター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019013227A JP2019013227A (ja) | 2019-01-31 |
| JP2019013227A5 true JP2019013227A5 (enExample) | 2019-03-22 |
| JP6889689B2 JP6889689B2 (ja) | 2021-06-18 |
Family
ID=43759252
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012529871A Active JP5806670B2 (ja) | 2009-09-16 | 2010-09-15 | プロテインキナーゼコンジュゲート及びインヒビター |
| JP2015174949A Ceased JP6397389B2 (ja) | 2009-09-16 | 2015-09-04 | プロテインキナーゼコンジュゲート及びインヒビター |
| JP2018163436A Expired - Fee Related JP6889689B2 (ja) | 2009-09-16 | 2018-08-31 | プロテインキナーゼコンジュゲート及びインヒビター |
| JP2021086337A Pending JP2021121219A (ja) | 2009-09-16 | 2021-05-21 | プロテインキナーゼコンジュゲート及びインヒビター |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012529871A Active JP5806670B2 (ja) | 2009-09-16 | 2010-09-15 | プロテインキナーゼコンジュゲート及びインヒビター |
| JP2015174949A Ceased JP6397389B2 (ja) | 2009-09-16 | 2015-09-04 | プロテインキナーゼコンジュゲート及びインヒビター |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021086337A Pending JP2021121219A (ja) | 2009-09-16 | 2021-05-21 | プロテインキナーゼコンジュゲート及びインヒビター |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9556426B2 (enExample) |
| EP (1) | EP2478361A4 (enExample) |
| JP (4) | JP5806670B2 (enExample) |
| KR (1) | KR20120093220A (enExample) |
| CN (2) | CN102713618B (enExample) |
| AU (2) | AU2010295690B2 (enExample) |
| BR (1) | BR112012005962A8 (enExample) |
| CA (1) | CA2773985A1 (enExample) |
| IL (1) | IL218678A0 (enExample) |
| IN (1) | IN2012DN02534A (enExample) |
| MX (1) | MX339811B (enExample) |
| NZ (2) | NZ620174A (enExample) |
| RU (1) | RU2012114902A (enExample) |
| SG (1) | SG179172A1 (enExample) |
| WO (1) | WO2011034907A2 (enExample) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA018573B1 (ru) | 2006-09-22 | 2013-09-30 | Фармасайкликс, Инк. | Ингибиторы тирозинкиназы брутона |
| US8809273B2 (en) | 2007-03-28 | 2014-08-19 | Pharmacyclics, Inc. | Inhibitors of Bruton's tyrosine kinase |
| MX2010012703A (es) | 2008-05-21 | 2010-12-21 | Ariad Pharma Inc | Derivados fosforosos como inhibidores de cinasa. |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| CN105362277A (zh) | 2008-07-16 | 2016-03-02 | 药品循环有限公司 | 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂 |
| MY156789A (en) * | 2008-09-05 | 2016-03-31 | Celgene Avilomics Res Inc | Algorithm for designing irreversible inhibitors |
| IN2012DN02534A (enExample) | 2009-09-16 | 2015-08-28 | Avila Therapeutics Inc | |
| WO2011060321A1 (en) | 2009-11-16 | 2011-05-19 | Chdi, Inc. | Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof |
| US20110269244A1 (en) | 2009-12-30 | 2011-11-03 | Petter Russell C | Ligand-directed covalent modification of protein |
| CA3007787C (en) | 2010-06-03 | 2020-03-10 | Pharmacyclics Llc | The use of inhibitors of bruton's tyrosine kinase (btk) |
| HUE029196T2 (en) * | 2010-06-04 | 2017-02-28 | Hoffmann La Roche | Aminoprimidine derivatives as LRRK2 modulators |
| SG189043A1 (en) | 2010-11-10 | 2013-05-31 | Hoffmann La Roche | Pyrazole aminopyrimidine derivatives as lrrk2 modulators |
| BR112013027734A2 (pt) | 2011-05-04 | 2017-08-08 | Ariad Pharma Inc | compostos para a inibição de proliferação celular em cânceres impulsionados pelo egfr, método e composição farmacêutica |
| US8889716B2 (en) | 2011-05-10 | 2014-11-18 | Chdi Foundation, Inc. | Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof |
| WO2013009827A1 (en) * | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| WO2013009812A1 (en) * | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc | Methods of treatment |
| WO2013009830A1 (en) * | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| WO2013009810A1 (en) * | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| EP2736895B1 (en) | 2011-07-27 | 2016-01-06 | Astrazeneca AB | 2-(2,4,5-substituted-anilino) pyrimidine derivatives as egfr modulators useful for treating cancer |
| CA2856291C (en) | 2011-11-17 | 2020-08-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
| AR089182A1 (es) * | 2011-11-29 | 2014-08-06 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de lrrk2 |
| KR20160125527A (ko) * | 2012-04-17 | 2016-10-31 | 후지필름 가부시키가이샤 | 함질소 복소환 화합물 또는 그 염 |
| AU2013204563B2 (en) | 2012-05-05 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| EA201492082A1 (ru) | 2012-06-04 | 2015-03-31 | Фармасайкликс, Инк. | Кристаллические формы ингибитора тирозинкиназы брутона |
| DK2872491T3 (da) | 2012-07-11 | 2021-08-09 | Blueprint Medicines Corp | Inhibitorer af fibroblastvækstfaktorreceptoren |
| CA2879570A1 (en) | 2012-07-24 | 2014-01-30 | Pharmacyclics, Inc. | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
| MX2015006168A (es) | 2012-11-15 | 2015-08-10 | Pharmacyclics Inc | Compuestos de pirrolopirimidina como inhibidores de quinasas. |
| RU2693480C2 (ru) | 2013-03-14 | 2019-07-03 | Толеро Фармасьютикалз, Инк. | Ингибиторы jak2 и alk2 и способы их использования |
| EP3943087A1 (en) | 2013-03-15 | 2022-01-26 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
| US9321786B2 (en) | 2013-03-15 | 2016-04-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| TWI649081B (zh) | 2013-08-02 | 2019-02-01 | 製藥公司 | 治療固態腫瘤之方法 |
| ES2709509T3 (es) | 2013-08-12 | 2019-04-16 | Pharmacyclics Llc | Procedimientos para el tratamiento de cáncer amplificado por HER2 |
| AU2014318614B2 (en) | 2013-09-12 | 2021-01-07 | Dana-Farber Cancer Institute Inc. | Methods for evaluating and treating Waldenstrom's macroglobulinemia |
| BR112016008849B8 (pt) | 2013-10-25 | 2022-09-06 | Blueprint Medicines Corp | Compostos ou sais farmaceuticamente aceitáveis dos mesmos, uso dos referidos compostos e composições farmacêuticas |
| US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| MA38393B1 (fr) * | 2014-03-13 | 2018-11-30 | Sanofi Sa | Composés hétéroaryle et utilisations associées |
| EP3119910A4 (en) | 2014-03-20 | 2018-02-21 | Pharmacyclics LLC | Phospholipase c gamma 2 and resistance associated mutations |
| LT3126352T (lt) | 2014-04-04 | 2019-01-10 | Syros Pharmaceuticals, Inc. | Nuo ciklino priklausomos kinazės 7 (cdk7) inhibitoriai |
| CN106999494A (zh) | 2014-08-01 | 2017-08-01 | 药品循环有限公司 | 布鲁顿酪氨酸激酶的抑制剂 |
| JP2017523206A (ja) | 2014-08-07 | 2017-08-17 | ファーマサイクリックス エルエルシー | ブルトン型チロシンキナーゼ阻害剤の新規製剤 |
| IL315294A (en) | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of bruton's tyrosine kinase inhibitor |
| EP4112618A1 (en) | 2015-06-03 | 2023-01-04 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| NZ743651A (en) | 2015-12-09 | 2023-07-28 | Univ Illinois | Benzothiophene-based selective estrogen receptor downregulators |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| ES2989988T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros heterorocíclicos para la degradación de proteínas diana |
| WO2017197051A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
| US11285218B2 (en) | 2016-06-23 | 2022-03-29 | Dana-Farber Cancer Institute, Inc. | Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use |
| EA201990187A1 (ru) | 2016-07-01 | 2019-07-31 | Г1 Терапьютикс, Инк. | Антипролиферационные средства на основе пиримидина |
| WO2018049233A1 (en) | 2016-09-08 | 2018-03-15 | Nicolas Stransky | Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors |
| WO2018187294A1 (en) * | 2017-04-03 | 2018-10-11 | Asana Biosciences, Llc | Pyrimido-pyridazinone compound combinations, methods, kits and formulations thereof |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| EP4455146A3 (en) | 2017-06-29 | 2025-01-01 | G1 Therapeutics, Inc. | Morphic forms of git38 and methods of manufacture thereof |
| WO2019024876A1 (zh) * | 2017-08-04 | 2019-02-07 | 上海和誉生物医药科技有限公司 | 一种具有fgfr4抑制活性的醛基吡啶衍生物、其制备方法和应用 |
| CN111902141A (zh) | 2018-03-26 | 2020-11-06 | C4医药公司 | 用于ikaros降解的羟脑苷脂结合剂 |
| IL259810A (en) * | 2018-06-04 | 2018-07-31 | Yeda Res & Dev | Mitogen-activated protein kinase kinase 7 inhibitors |
| CA3103995A1 (en) | 2018-07-26 | 2020-01-30 | Sumitomo Dainippon Pharma Oncology, Inc. | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same |
| KR102328682B1 (ko) * | 2018-08-27 | 2021-11-18 | 주식회사 대웅제약 | 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물 |
| WO2020045941A1 (ko) * | 2018-08-27 | 2020-03-05 | 주식회사 대웅제약 | 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물 |
| WO2020051235A1 (en) | 2018-09-04 | 2020-03-12 | C4 Therapeutics, Inc. | Compounds for the degradation of brd9 or mth1 |
| WO2020097400A1 (en) | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof |
| US12522583B2 (en) | 2018-11-07 | 2026-01-13 | Dana-Farber Cancer Institute, Inc. | Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof |
| US12415816B2 (en) | 2018-11-07 | 2025-09-16 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| CA3124569A1 (en) | 2018-12-28 | 2020-07-02 | Spv Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
| CN113645976A (zh) | 2019-03-29 | 2021-11-12 | 阿斯利康(瑞典)有限公司 | 用于治疗非小细胞肺癌的奧希替尼 |
| KR20210152515A (ko) | 2019-04-12 | 2021-12-15 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
| JP7628108B2 (ja) * | 2019-07-19 | 2025-02-07 | ブリッドジーン バイオサイエンシズ インコーポレイテッド | チロシンキナーゼの阻害剤 |
| MX2022007659A (es) | 2019-12-20 | 2022-07-19 | C4 Therapeutics Inc | Compuestos de isoindolinona e indazol para la degradacion del receptor del factor de crecimiento epidermico (egfr). |
| MX2022010952A (es) | 2020-03-05 | 2022-10-07 | C4 Therapeutics Inc | Compuestos para la degradacion dirigida de brd9. |
| TW202204350A (zh) | 2020-05-06 | 2022-02-01 | 美商雅捷可斯治療公司 | 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑 |
| EP4652997A3 (en) | 2020-05-19 | 2026-03-04 | Pharmacosmos Holding A/s | Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders |
| JP2023538517A (ja) | 2020-08-05 | 2023-09-08 | シーフォー セラピューティクス， インコーポレイテッド | Ｒｅｔの標的分解のための化合物 |
| JP7787164B2 (ja) | 2020-09-23 | 2025-12-16 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 補体媒介性障害の治療のための医薬化合物 |
| US12043632B2 (en) | 2020-12-23 | 2024-07-23 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
| CN117940133A (zh) | 2021-06-08 | 2024-04-26 | C4医药公司 | 用于突变braf的降解的治疗剂 |
| CA3234638A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| WO2023086320A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of jak2 |
| WO2023107705A1 (en) | 2021-12-10 | 2023-06-15 | Incyte Corporation | Bicyclic amines as cdk12 inhibitors |
| TW202345806A (zh) | 2022-03-31 | 2023-12-01 | 美商艾伯維有限公司 | 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑 |
| EP4565585A1 (en) | 2022-08-03 | 2025-06-11 | Bristol-Myers Squibb Company | Compounds for modulating ret protein |
| JP2025540907A (ja) | 2022-11-04 | 2025-12-17 | ブリストル－マイヤーズ スクイブ カンパニー | Ｒｅｔ－ｌｄｄタンパク質分解誘導剤 |
| CN120530116A (zh) | 2022-11-04 | 2025-08-22 | 百时美施贵宝公司 | Ret-ldd蛋白抑制剂 |
| WO2025006753A2 (en) | 2023-06-30 | 2025-01-02 | Merck Patent Gmbh | Heterobifunctional compounds for the degradation of kras protein |
| CN118766549A (zh) * | 2024-06-24 | 2024-10-15 | 重庆医科大学附属第一医院 | 脊柱转移性肿瘤微创切吸治疗系统 |
Family Cites Families (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| US5516931A (en) | 1982-02-01 | 1996-05-14 | Northeastern University | Release tag compounds producing ketone signal groups |
| US4650750A (en) | 1982-02-01 | 1987-03-17 | Giese Roger W | Method of chemical analysis employing molecular release tag compounds |
| US5650270A (en) | 1982-02-01 | 1997-07-22 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| US4709016A (en) | 1982-02-01 | 1987-11-24 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| US5756466A (en) | 1994-06-17 | 1998-05-26 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| US5856116A (en) | 1994-06-17 | 1999-01-05 | Vertex Pharmaceuticals, Incorporated | Crystal structure and mutants of interleukin-1 beta converting enzyme |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| HU228446B1 (en) | 1996-04-12 | 2013-03-28 | Warner Lambert Co | Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof |
| ES2285735T3 (es) | 1996-07-25 | 2007-11-16 | Biogen Idec Inc | Modelo molecular para inhibidores de vla-4. |
| US6686350B1 (en) | 1996-07-25 | 2004-02-03 | Biogen, Inc. | Cell adhesion inhibitors |
| ATE290545T1 (de) | 1996-12-06 | 2005-03-15 | Vertex Pharma | Inhibitoren des interleukin-1beta konvertierenden enzyms |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| US6251912B1 (en) | 1997-08-01 | 2001-06-26 | American Cyanamid Company | Substituted quinazoline derivatives |
| US6162613A (en) | 1998-02-18 | 2000-12-19 | Vertex Pharmaceuticals, Inc. | Methods for designing inhibitors of serine/threonine-kinases and tyrosine kinases |
| US7383135B1 (en) | 1998-05-04 | 2008-06-03 | Vertex Pharmaceuticals Incorporated | Methods of designing inhibitors for JNK kinases |
| US6335155B1 (en) | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
| US6919178B2 (en) | 2000-11-21 | 2005-07-19 | Sunesis Pharmaceuticals, Inc. | Extended tethering approach for rapid identification of ligands |
| EP1115847A1 (en) * | 1998-09-25 | 2001-07-18 | Children's Medical Center Corporation | Short peptides which selectively modulate the activity of protein kinases |
| US6288082B1 (en) | 1998-09-29 | 2001-09-11 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| EP1131304B1 (en) | 1998-11-19 | 2002-12-04 | Warner-Lambert Company | N- 4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases |
| US6569876B1 (en) | 1999-06-17 | 2003-05-27 | John C. Cheronis | Method and structure for inhibiting activity of serine elastases |
| US6420364B1 (en) | 1999-09-13 | 2002-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compound useful as reversible inhibitors of cysteine proteases |
| AU2001236720A1 (en) | 2000-02-05 | 2001-08-14 | Bemis, Guy | Compositions useful as inhibitors of erk |
| US6384051B1 (en) | 2000-03-13 | 2002-05-07 | American Cyanamid Company | Method of treating or inhibiting colonic polyps |
| US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| CA2417500C (en) | 2000-07-28 | 2008-11-18 | Georgetown University Medical Center | Erbb-2 selective small molecule kinase inhibitors |
| WO2002014281A1 (en) | 2000-08-11 | 2002-02-21 | Vertex Pharmaceuticals Incorporated | Pyridine derivatives as inhibitors of p38 |
| HUP0400639A3 (en) | 2000-12-21 | 2010-03-29 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them |
| US7235576B1 (en) | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| IL144583A0 (en) * | 2001-07-26 | 2002-05-23 | Peptor Ltd | Chimeric protein kinase inhibitors |
| IL161409A0 (en) | 2001-11-21 | 2004-09-27 | Sunesis Pharmaceuticals Inc | Methods for ligand discovery |
| ATE387002T1 (de) | 2001-12-07 | 2008-03-15 | Res Investment Network Inc | Aus festkörper gebildetes mikrooptisches elektromechanisches system (moems) zur wiedergabe eines photonischen diffraktiven speichers |
| CA2472580A1 (en) | 2002-01-07 | 2003-07-17 | Sequoia Pharmaceuticals | Broad spectrum inhibitors |
| US7202033B2 (en) | 2002-03-21 | 2007-04-10 | Sunesis Pharmaceuticals, Inc. | Identification of kinase inhibitors |
| GB0213186D0 (en) | 2002-06-08 | 2002-07-17 | Univ Dundee | Methods |
| MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| EP1375517A1 (en) | 2002-06-21 | 2004-01-02 | Smithkline Beecham Corporation | Structure of a glucocorticoid receptor ligand binding domain comprising an expanded binding pocket and methods employing same |
| GB0221169D0 (en) | 2002-09-12 | 2002-10-23 | Univ Bath | Crystal |
| EA200500721A1 (ru) | 2002-11-28 | 2005-12-29 | Шеринг Акциенгезельшафт | Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств |
| PE20040945A1 (es) | 2003-02-05 | 2004-12-14 | Warner Lambert Co | Preparacion de quinazolinas substituidas |
| CA2515688A1 (en) * | 2003-02-11 | 2004-08-26 | Immusol Incorporated | Sirna libraries optimized for predetermined protein families |
| JP4927533B2 (ja) | 2003-02-28 | 2012-05-09 | ニッポネックス インコーポレイテッド | 癌その他の疾患の治療に有用な置換ピリジン誘導体 |
| UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
| ATE489379T1 (de) | 2003-02-28 | 2010-12-15 | Bayer Healthcare Llc | 2-oxo-1,3,5-perhydrotriazapinderivate, die sich zur behandlung von hyperproliferativen, angiogenen und entzündlichen erkrankungen eignen |
| EP1610808A4 (en) | 2003-03-26 | 2011-04-06 | Sudhir Paul | COVALENT BINDING OF LIGANDS TO NUCLEOPHILIC PROTEINS UNDER GUIDANCE BY NONCOVALENT BINDING |
| WO2007038613A2 (en) | 2005-09-26 | 2007-04-05 | The Regents Of The University Of California | Selective serine/threonine kinase inhibitors |
| US7687506B2 (en) | 2003-04-11 | 2010-03-30 | The Regents Of The University Of California | Selective serine/threonine kinase inhibitors |
| WO2004113274A2 (en) | 2003-05-20 | 2004-12-29 | Bayer Pharmaceuticals Corporation | Diaryl ureas with kinase inhibiting activity |
| EP1648516A2 (en) | 2003-08-01 | 2006-04-26 | Wyeth Holdings Corporation | Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer |
| GB0321710D0 (en) | 2003-09-16 | 2003-10-15 | Novartis Ag | Organic compounds |
| WO2005034840A2 (en) | 2003-09-17 | 2005-04-21 | Sunesis Pharmaceuticals, Inc. | Identification of kinase inhibitors |
| WO2005043118A2 (en) | 2003-10-27 | 2005-05-12 | Vertex Pharmaceuticals Incorporated | Drug discovery method |
| US7932382B2 (en) | 2004-01-16 | 2011-04-26 | The Regents Of The University Of Michigan | Conformationally constrained Smac mimetics and the uses thereof |
| AU2005211448A1 (en) * | 2004-01-30 | 2005-08-18 | Merck Patent Gmbh | Bisarylurea derivatives |
| US20080268460A1 (en) | 2004-05-20 | 2008-10-30 | Wyeth | Assays to Identify Irreversibly Binding Inhibitors of Receptor Tyrosine Kinases |
| WO2005115145A2 (en) | 2004-05-20 | 2005-12-08 | Wyeth | Quinone substituted quinazoline and quinoline kinase inhibitors |
| US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| US20060079494A1 (en) | 2004-09-27 | 2006-04-13 | Santi Daniel V | Specific kinase inhibitors |
| JP5089392B2 (ja) | 2004-10-13 | 2012-12-05 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | キナーゼ阻害剤としての複素環式置換ビスアリール尿素誘導体 |
| ZA200706804B (en) | 2005-02-03 | 2008-10-29 | Gen Hospital Corp | Method for treating gefitinib resistant cancer |
| KR20080002826A (ko) | 2005-04-14 | 2008-01-04 | 와이어쓰 | 게피티니브 내성 환자에서의 표피 성장 인자 수용체（ｅｇｆｒ） 키나제 억제제의 용도 |
| AR053602A1 (es) | 2005-05-03 | 2007-05-09 | Smithkline Beecham Corp | Compuesto de 2- arilamino -4-oxo-1,3-tiazol-5(4h)- substituido, composicion farmaceutica que lo comprende, proceso para prepararla y uso del compuesto para preparar un medicamento |
| CA2607020C (en) | 2005-05-05 | 2015-01-13 | Chroma Therapeutics Ltd. | Alpha amino acid ester-drug conjugates hydrolysable by carboxylesterases |
| GB0509224D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of intracellular enzymatic activity |
| WO2006125539A2 (en) | 2005-05-27 | 2006-11-30 | Bayer Healthcare Ag | Combination therapy comprising diaryl ureas for treating diseases |
| NZ567851A (en) | 2005-11-01 | 2011-09-30 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
| TW200734327A (en) | 2005-11-03 | 2007-09-16 | Vertex Pharma | Aminopyrimidines useful as kinase inhibitors |
| WO2007062459A1 (en) | 2005-11-29 | 2007-06-07 | Cytopia Research Pty Ltd | Selective kinase inhibitors based on pyridine scaffold |
| JP2009520038A (ja) | 2005-12-19 | 2009-05-21 | ジェネンテック・インコーポレーテッド | ピリミジンキナーゼインヒビター |
| TW200736232A (en) | 2006-01-26 | 2007-10-01 | Astrazeneca Ab | Pyrimidine derivatives |
| CA2647271A1 (en) | 2006-04-07 | 2007-10-18 | Modpro Ab | Binder for c-reactive protein |
| CN101054380B (zh) | 2006-04-13 | 2011-07-20 | 沈阳药科大学 | 用作细胞周期依赖性蛋白激酶抑制剂的吡唑并嘧啶类衍生物 |
| US7601852B2 (en) | 2006-05-11 | 2009-10-13 | Kosan Biosciences Incorporated | Macrocyclic kinase inhibitors |
| US8604031B2 (en) * | 2006-05-18 | 2013-12-10 | Mannkind Corporation | Intracellular kinase inhibitors |
| PE20080403A1 (es) * | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| US8217177B2 (en) * | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| US8198448B2 (en) * | 2006-07-14 | 2012-06-12 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| EA018573B1 (ru) * | 2006-09-22 | 2013-09-30 | Фармасайкликс, Инк. | Ингибиторы тирозинкиназы брутона |
| US8193197B2 (en) | 2006-10-19 | 2012-06-05 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
| ME00811B (me) | 2006-12-08 | 2012-03-20 | Novartis Ag | JEDINJENJA l KOMPOZICIJE KAO INHIBITORI PROTEIN KINAZE |
| EP2099771A1 (en) | 2006-12-19 | 2009-09-16 | Genentech, Inc. | Pyrimidine kinase inhibitors |
| PT2114900T (pt) | 2007-01-31 | 2019-01-17 | Ym Biosciences Australia Pty | Compostos à base de tiopirimidina e as suas utilizações |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| EP2152079A4 (en) | 2007-06-04 | 2011-03-09 | Avila Therapeutics Inc | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| WO2009030890A1 (en) | 2007-09-03 | 2009-03-12 | University Court Of The University Of Dundee | Pyrimidine compounds for the treatment of cancer, septic shock and/or primary open angle glaucoma |
| US7989465B2 (en) | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
| EP2214486A4 (en) | 2007-10-19 | 2011-03-09 | Avila Therapeutics Inc | HETEROARYL COMPOUNDS AND ITS USES |
| US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
| TWI487522B (zh) | 2007-12-21 | 2015-06-11 | 賽基艾維洛米斯研究股份有限公司 | Ｈｃｖ蛋白酶抑制劑及其用途（一） |
| US8309685B2 (en) | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
| TW200932255A (en) | 2007-12-21 | 2009-08-01 | Avila Therapeutics Inc | HCV protease inhibitors and uses thereof |
| EP2244721A4 (en) | 2008-01-14 | 2017-01-18 | Bayer Intellectual Property GmbH | Sulfone substituted 2,3-dihydroimidazo ý1,2-c¨quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| SG10201510696RA (en) | 2008-06-27 | 2016-01-28 | Celgene Avilomics Res Inc | Heteroaryl compounds and uses thereof |
| US8188137B2 (en) | 2008-08-15 | 2012-05-29 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
| MY156789A (en) | 2008-09-05 | 2016-03-31 | Celgene Avilomics Res Inc | Algorithm for designing irreversible inhibitors |
| US8603737B2 (en) | 2008-09-19 | 2013-12-10 | Celgene Avilomics Research, Inc. | Methods for identifying HCV protease inhibitors |
| WO2011031896A2 (en) | 2009-09-09 | 2011-03-17 | Avila Therapeutics, Inc. | Pi3 kinase inhibitors and uses thereof |
| IN2012DN02534A (enExample) | 2009-09-16 | 2015-08-28 | Avila Therapeutics Inc | |
| US20110269244A1 (en) | 2009-12-30 | 2011-11-03 | Petter Russell C | Ligand-directed covalent modification of protein |
| MY160734A (en) | 2010-08-10 | 2017-03-15 | Celgene Avilomics Res Inc | Besylate salt of a btk inhibitor |
-
2010
- 2010-09-15 IN IN2534DEN2012 patent/IN2012DN02534A/en unknown
- 2010-09-15 WO PCT/US2010/048916 patent/WO2011034907A2/en not_active Ceased
- 2010-09-15 AU AU2010295690A patent/AU2010295690B2/en not_active Ceased
- 2010-09-15 CN CN201080050753.3A patent/CN102713618B/zh not_active Expired - Fee Related
- 2010-09-15 SG SG2012018545A patent/SG179172A1/en unknown
- 2010-09-15 RU RU2012114902/04A patent/RU2012114902A/ru not_active Application Discontinuation
- 2010-09-15 BR BR112012005962A patent/BR112012005962A8/pt not_active IP Right Cessation
- 2010-09-15 CA CA2773985A patent/CA2773985A1/en not_active Abandoned
- 2010-09-15 NZ NZ620174A patent/NZ620174A/en not_active IP Right Cessation
- 2010-09-15 NZ NZ598705A patent/NZ598705A/en not_active IP Right Cessation
- 2010-09-15 KR KR1020127009760A patent/KR20120093220A/ko not_active Ceased
- 2010-09-15 US US12/882,484 patent/US9556426B2/en active Active
- 2010-09-15 MX MX2012003332A patent/MX339811B/es active IP Right Grant
- 2010-09-15 EP EP10817748.6A patent/EP2478361A4/en not_active Withdrawn
- 2010-09-15 JP JP2012529871A patent/JP5806670B2/ja active Active
- 2010-09-15 CN CN201510330338.8A patent/CN105063001A/zh active Pending
-
2012
- 2012-03-15 IL IL218678A patent/IL218678A0/en unknown
-
2015
- 2015-09-04 JP JP2015174949A patent/JP6397389B2/ja not_active Ceased
-
2016
- 2016-07-18 US US15/213,319 patent/US10662195B2/en active Active
- 2016-10-24 AU AU2016250339A patent/AU2016250339A1/en not_active Abandoned
-
2018
- 2018-08-31 JP JP2018163436A patent/JP6889689B2/ja not_active Expired - Fee Related
-
2021
- 2021-05-21 JP JP2021086337A patent/JP2021121219A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019013227A5 (enExample) | ||
| JP2013505245A5 (enExample) | ||
| KR0167395B1 (ko) | 부신피질자극호르몬-방출인자 길항제로서의 피라졸로피리미딘 | |
| AU2015353210B2 (en) | 2-aminopyrimidine compound and pharmaceutical composition and use thereof | |
| RU2020123151A (ru) | Антагонисты tlr7/8 и их применение | |
| RU2008116844A (ru) | Ацилированные производные спиропиперидина как модуляторы рецептора меланокортина-4 | |
| TW200306836A (en) | Condensed pyridazine derivative and medicament containing same as active ingredient | |
| CN105008358B (zh) | 人免疫缺陷病毒复制的抑制剂 | |
| CY1110676T1 (el) | ΠΥΡΑΖΟΛΟ[3,4-b]ΠΥΡΙΔΙΝΙΚΕΣ ΕΝΩΣΕΙΣ, ΚΑΙ Η ΧΡΗΣΗ ΤΟΥΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ ΦΩΣΦΟΔΙΕΣΤΕΡΑΣΗΣ | |
| WO2019008506A1 (en) | N- (3- (2- (4-CHLOROPHENOXY) ACETAMIDO) BICYCLO [1.1.1] PENTAN-1-YL) -2-CYCLOBUTANE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER DISEASES | |
| RU2014103960A (ru) | Гетероарилзамещенные пиразолопиридины и их применение в качестве стимуляторов растворимой гуанилатциклазы | |
| RU2006134020A (ru) | Конденсированные производные пиразола | |
| CN103124730A (zh) | 杂环炔苯类化合物及其药用组合物和应用 | |
| JP2005537247A (ja) | 置換されたキノリンｃｃｒ５受容体アンタゴニスト | |
| WO2020031107A1 (en) | Chemical compounds | |
| JP2011510004A (ja) | タンパク質キナーゼ阻害剤及びその使用 | |
| AR030053A1 (es) | 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas | |
| ES2875737T3 (es) | Derivados de 2-fenil-3H-imidazo[4,5-b]piridina útiles como inhibidores de la actividad tirosina quinasa de ROR1 de mamíferos | |
| AR099498A1 (es) | Compuestos de triazina y su uso farmacéutico | |
| JP2022537521A (ja) | 小分子標的ブロモ／アセチルタンパク質およびその使用 | |
| JP2016525104A5 (enExample) | ||
| JP2022533182A (ja) | タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用 | |
| AR035877A1 (es) | Derivados de n-oxido-antranilamida, su uso para preparar un medicamento y los medicamentos que los contienen | |
| RU2009149518A (ru) | Триазоло[1, 5-а]хинолины в качестве лигандов рецептора аденозина а3 | |
| PE20231097A1 (es) | Compuestos heterociclicos como inhibidores de delta-5 desaturasa y metodos de uso |